RecruitingPhase 3NCT07160634

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

Sponsor

Solid Biosciences Inc.

Enrollment

80 participants

Start Date

Oct 22, 2025

Study Type

INTERVENTIONAL

Conditions

Duchenne Muscular Dystrophy

Summary

This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date.

Eligibility

Sex: MALEMin Age: 7 YearsMax Age: 11 Years

Inclusion Criteria7

Participant is ambulatory.
Established clinical diagnosis of DMD and documented DMD gene mutation predictive of DMD phenotype.
Negative for antibodies against adeno-associated virus.
On a stable daily oral regimen of at least 0.5 mg/kg/day prednisone or 0.75 milligrams per kilogram per day (mg/kg/day) deflazacort for at least 6 months prior to entering the study, allowing for weight-based dose modifications in accordance with clinical practice.
Meet 10-meter walk/run time criteria.
Meet time to rise from supine criteria.
Participant has bodyweight ≤50 kg.

Exclusion Criteria3

Current or prior treatment with an approved or investigational gene transfer drug or gene editing therapy.
Exposure to vamorolone, givinostat, approved or investigational dystrophin- or disease-modifying drugs (such as eteplirsen, golodirsen, casimersen, viltolarsen, and ataluren), or another investigational drug for any indication within 6 months or 5 half-lives, whichever is longer, prior to enrollment.
Established clinical diagnosis of DMD that is associated with any deletion variant or variant predicted not to express exons 1 to 11, exons 42 to 45, or exons 57 to 69, inclusive of the DMD gene as documented by a genetic report.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.